Zydus Lifesciences Ltd. announced its unaudited consolidated financial results for the quarter and nine months ended December 31st, 2024. Key Financial Highlights Q3 FY25 Highlights Revenue from operations at Rs. 52,691 mn, up 17% over last year. Research & Development (R&D) investments for the quarter stood
Zydus Lifesciences Limited (including its subsidiaries/ affiliates, hereafter referred to as “Zydus”) today announced that the Mexican regulatory authority COFEPRIS (Federal Commission for the Protection Against Sanitary Risk), has granted marketing approval for MamitraTM, a Trastuzumab biosimilar. The drug will be marketed in different strengths
